COVID Vaccination Reduced Risk for Hospitalization 65+ Years of Age

Mary Madison, RN, RAC-CT, CDP Clinical Consultant – Briggs Healthcare The April 28, 2021 Early Release of this week’s MMWR (CDC’s Morbidity and Mortality Weekly Report) provides this very encouraging information! Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 “In the current report, Pfizer-BioNTech and…… Continue reading COVID Vaccination Reduced Risk for Hospitalization 65+ Years of Age

Leadership, Management and Safe Operations – AHRQ COVID-19 Resources

Mary Madison, RN, RAC-CT, CDPClinical Consultant – Briggs Healthcare During April 2021, AHRQ (Agency for Healthcare Research and Quality) created a landing page that is filled with resources to assist LTCFs.  It’s a website you’ll want to bookmark and check periodically for additional information. “Nursing home administrators and others may benefit from the following specific…… Continue reading Leadership, Management and Safe Operations – AHRQ COVID-19 Resources

CDC Updates Interim Public Health Recommendations for Fully Vaccinated People

Mary Madison, RN, RAC-CT, CDP Clinical Consultant – Briggs Healthcare CDC updated both the recommendations for fully vaccinated people and Healthcare Infection Prevention and Control Recommendations in Response to COVID-19 Vaccination on April 27, 2021. The former hyperlink contains these overall updates: The latter hyperlink above contains these overall updates: You’ll see the following graphic on…… Continue reading CDC Updates Interim Public Health Recommendations for Fully Vaccinated People

FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use

Mary Madison, RN, RAC-CT, CDPClinical Consultant – Briggs Healthcare “Following a thorough safety review, including two meetings of the CDC’s Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen)…… Continue reading FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use

COVID-19 LTC Deaths and Cases Are at An All-Time Low, Though a Rise In LTC Cases in a Few States May Be Cause for Concern

Mary Madison, RN, RAC-CT, CDPClinical Consultant – Briggs Healthcare The title of this blog is also the title of a just-released Kaiser Family Foundation (KFF) report.   I’m providing two (2) of the tables with corresponding data notes for this blog in hope that your interest will be tweaked and you read the entire report.  You…… Continue reading COVID-19 LTC Deaths and Cases Are at An All-Time Low, Though a Rise In LTC Cases in a Few States May Be Cause for Concern

COVID-19 Update: FDA Revoked the EUA for Bamlanivimab When Administered Alone

Mary Madison, RN, RAC-CT, CDPClinical Consultant – Briggs Healthcare Yesterday (April 20, 2021) I blogged on this FDA announcement.  Later in the day, CMS published a Special Edition – MLN Connects that provides this information: On April 16, the FDA revoked the Emergency Use Authorization (EUA) for bamlanivimab, when administered alone, due to a sustained increase…… Continue reading COVID-19 Update: FDA Revoked the EUA for Bamlanivimab When Administered Alone

Renewal of Determination That A Public Health Emergency Exists

Mary Madison, RN, RAC-CT, CDPClinical Consultant – Briggs Healthcare HHS Secretary Xavier Becerra renewed this PHE declaration on April 15, 2021: Note that this website provides links to additional resources for emergency and response information, including EUAs and Section 1135 Waivers. If you remember, HHS extended the PHE through the end of 2021 at a…… Continue reading Renewal of Determination That A Public Health Emergency Exists

Updated COVID-19 Information as of April 20, 2021

Mary Madison, RN, RAC-CT, CDPClinical Consultant – Briggs Healthcare FDA Revoked Emergency Use Authorization for Monoclonal Antibody Bamlanivimab on Friday, April 16, 2021.  The U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults…… Continue reading Updated COVID-19 Information as of April 20, 2021